Breckenridge Pharmaceutical Inc has launched Everolimus Tablets, 1mg, a generic version of Zortress by Novartis, under the therapeutic class of immunosuppressant. This product was developed in collaboration with Natco Pharma, India. The product is expected to be available starting October 30, 2025.

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation. The product will be available predominantly in retail, mail order pharmacies, as well as clinics.

"We are excited to now offer all strengths of Everolimus Tablets in both bottles and blister card configurations. Breckenridge previously launched its Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths, with blisters launched in July 2021 and bottles launched in June 2023. We continue to focus on the development of therapies that provide affordable access to all patients and address unmet medical needs," stated Brian Guy, President and CCO, Breckenridge Pharmaceutical, Inc.